OPK — OPKO Health, Inc.

OPKO Health Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $148.5 million, down from $183.6 million in Q4 2024.
• Diagnostics Revenue: $71.1 million, including $7 million from the 4Kscore test, which grew 16% year-over-year.
• Pharmaceutical Revenue: $77.4 million, a slight decrease from $80.5 million in Q4 2024.
• Operating Loss: $38.3 million, compared to a $33.1 million loss in Q4 2024.
• Net Loss: $31.3 million ($0.04 per share), compared to a net income of $14 million in Q4 2024.
• Cash Position: $369 million, allowing for continued operations and share repurchases.

2. Strategic Updates and Business Highlights

• Diagnostics Transformation: Completed the sale of BioReference's oncology assets to Labcorp, focusing on core clinical laboratory services and the 4Kscore test.
• ModeX Pipeline: Advancements in multiple clinical-stage programs, including an EBV vaccine partnered with Merck and various immuno-oncology candidates.
• Collaboration with Regeneron: A partnership with potential milestones exceeding $1 billion, focusing on antibody development in metabolism, oncology, and immunology.
• Cost Reduction Initiatives: Workforce reduction of 29% and other operational efficiencies have improved margins.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $125 million and $140 million, with service revenue of $71 million to $75 million.
• Full Year 2026 Revenue Guidance: Anticipated total revenue of $530 million to $560 million, with pharmaceutical product revenue of $160 million to $170 million.
• R&D Investment: Expected between $125 million and $135 million for 2026, reflecting ongoing development in the ModeX pipeline.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Total revenue decreased significantly compared to Q4 2024, primarily due to the Labcorp transaction and changes in test mix.
• Operating Losses: Increased operating loss in both diagnostics and pharmaceuticals, highlighting ongoing challenges in achieving profitability.
• Market Conditions: Weather impacts in early 2026 are expected to negatively affect revenue by $3 million to $5 million.
• Dependency on Partnerships: Future revenue growth is heavily reliant on successful collaborations and the performance of partnered products.

5. Notable Q&A Insights

• MDX2001 and MDX2004: Expectations for data disclosures and progress in clinical trials were discussed, with MDX2001 moving to Phase Ib by the end of 2026.
• 4Kscore Growth: Current growth is primarily driven by urology, with potential for acceleration as the company works on payer coverage for primary care.
• Regeneron Collaboration: Insights into the profit share from NGENLA indicated strong growth, with expectations for continued success based on Pfizer's market performance.
• EBV Vaccine Studies: Ongoing studies aim to refine the target population and prepare for Phase II trials, with data expected by the end of 2026.

This summary encapsulates the key points from OPKO Health's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, and future outlook while addressing challenges faced by the company.